''Highly exposed Chinese herbal medicine'' combined with apatinib as maintenance treatment following first-line or second-line chemotherapy for extensive-stage small-cell lung cancer: A single-arm
- Conditions
- small cell lung cancer
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- Not specified
The inclusion criteria were as follows:
1) with small-cell lung cancer (extensive stage);
2) aged between 18 and 70 years;
3) with at least one measurable lesion (according to the CT/MRI evaluation, the maximum diameter of the tumor was >10 mm), according to the RECIST1.1 criteria;
4) had already undergone 4-6 cycles of first-line or second-line chemotherapy, and were in the status of SD;
5) with the ECOG score of 0-2 points.
1) those treated with other anti-angiogenesis drugs;
2) allergic to apatinib;
3) could not tolerate long-term Chinese herbal medicine treatment;
4) accompanied with cardiovascular diseases (such as heart diseases or uncontrolled hypertension) or hematological diseases;
5) with liver or renal insufficiency;
6) with severe psychological disorders and could not adhere to the treatment;
7) with poor compliance and high risk of loss to follow up;
8) with hemorrhagic tendency;
9) underwent major surgeries within 28 d before participating in this study;
10) with perforation or abdominal fistula within 28 d before participating in this study.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse reactions;Disease control rate;Correlation between high exposure to traditional Chinese medicine and PFS or OS;Objective remission rate;Progression free survival;Overall survival;
- Secondary Outcome Measures
Name Time Method